The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy

INTRODUCTION: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Chiodi, Francesca, Nardozza, Aurelio Pio, Valsecchi, Diletta, Perrone, Valentina, Sangiorgi, Diego, Giacomini, Elisa, Rendace, Maria Chiara, Coco, Paola, Premoli, Eleonora, Degli Esposti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989002/
https://www.ncbi.nlm.nih.gov/pubmed/36562943
http://dx.doi.org/10.1007/s12325-022-02398-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989002/
https://www.ncbi.nlm.nih.gov/pubmed/36562943
http://dx.doi.org/10.1007/s12325-022-02398-6

Ejemplares similares